Scott  Lish net worth and biography

Scott Lish Biography and Net Worth

SVP of Alphatec
Scott Lish has served as Senior Vice President, Research and Development since October 2020. Mr. Lish began his career at Alphatec Spine as Vice President, Research and Development in October 2017. Prior to joining ATEC, Scott held various product development roles throughout an over 8 year tenure at NuVasive, Inc., where he most recently served as Director of Development, responsible for Thoracolumbar Fixation product development. Prior to joining NuVasive, Mr. Lish worked for 2 years as a Manufacturing Engineer for Zimmer Dental. Mr. Lish received an M.S. degree in Material Science and a B.E. degree in Mechanical Engineering from the Thayer School of Engineering at Dartmouth, as well as a B.A. degree in Engineering Sciences from Dartmouth College.

What is Scott Lish's net worth?

The estimated net worth of Scott Lish is at least $8.23 million as of February 27th, 2025. Mr. Lish owns 844,494 shares of Alphatec stock worth more than $8,233,817 as of April 14th. This net worth approximation does not reflect any other investments that Mr. Lish may own. Learn More about Scott Lish's net worth.

How old is Scott Lish?

Mr. Lish is currently 45 years old. There are 6 older executives and no younger executives at Alphatec. The oldest executive at Alphatec is Mr. Jonathan Allen, Executive Vice President of Commercial Operations, who is 64 years old. Learn More on Scott Lish's age.

How do I contact Scott Lish?

The corporate mailing address for Mr. Lish and other Alphatec executives is 5818 EL CAMINO REAL, CARLSBAD CA, 92008. Alphatec can also be reached via phone at (760) 431-9286 and via email at ir@alphatecspine.com. Learn More on Scott Lish's contact information.

Has Scott Lish been buying or selling shares of Alphatec?

Scott Lish has not been actively trading shares of Alphatec within the last three months. Most recently, Scott Lish sold 23,183 shares of the business's stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $12.03, for a transaction totalling $278,891.49. Following the completion of the sale, the chief operating officer now directly owns 844,494 shares of the company's stock, valued at $10,159,262.82. Learn More on Scott Lish's trading history.

Who are Alphatec's active insiders?

Alphatec's insider roster includes Evan Bakst (Director), Jeffrey Black (CFO), David Demski (Director), Jason Hochberg (Director), Craig Hunsaker (EVP), John Koning (Chief Financial Officer), Scott Lish (SVP), Tyson Marshall (General Counsel & Corporate Secretary), Patrick Miles (CEO), David Mowry (Director), David Pelizzon (Director), Jennifer Pritzker (Major Shareholder), Paul Segal (Major Shareholder), David Sponsel (EVP), and James Tullis (Director). Learn More on Alphatec's active insiders.

Are insiders buying or selling shares of Alphatec?

In the last twelve months, Alphatec insiders bought shares 1 times. They purchased a total of 50,000 shares worth more than $283,500.00. In the last twelve months, insiders at the medical technology company sold shares 14 times. They sold a total of 425,053 shares worth more than $4,855,334.27. The most recent insider tranaction occured on March, 7th when CEO Patrick Miles sold 12,691 shares worth more than $135,032.24. Insiders at Alphatec own 22.8% of the company. Learn More about insider trades at Alphatec.

Information on this page was last updated on 3/7/2025.

Scott Lish Insider Trading History at Alphatec

See Full Table

Scott Lish Buying and Selling Activity at Alphatec

This chart shows Scott Lish's buying and selling at Alphatec by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$500k$0$500kTotal Insider BuyingTotal Insider Selling

Alphatec Company Overview

Alphatec logo
Alphatec Holdings, Inc., a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems. It also provides split-blade retractors; Sigma-ALIF Access System, a procedure-specific access system; spinal implants and fixation systems comprising NanoTec surface modifications, Calibrate PSX, and Invictus, as well as various standalone implants for height restoration and stabilization. In addition, the company provides biologics comprising 3D ProFuse Osteoconductive Bioscaffold for ease of handling and better endplate-to-endplate contact; AlphaGRAFT Demineralized Bone Matrix (DBM) comprising demineralized human tissues; AlphaGRAFT DBM Fibers comprising demineralized fibers; AlphaGRAFT Cellular Bone Matrix (CBM), a growth factor-enriched cellular bone matrix; AlphaGRAFT CBM that is delivered in granular, fiber, or structural form; BioCORE Moldable Bioactive Graft, a synthetic mineral-collagen composite matrix that can be molded to fit the bone defect; and Amnioshield Amniotic Tissue Barrier, an allograft for spinal surgical barrier applications. The company sells its products through a network of independent sales agents and direct sales representatives. Alphatec Holdings, Inc. was founded in 1990 and is headquartered in Carlsbad, California.
Read More

Today's Range

Now: $9.75
Low: $9.25
High: $9.82

50 Day Range

MA: $10.47
Low: $9.27
High: $12.53

2 Week Range

Now: $9.75
Low: $4.88
High: $13.79

Volume

1,409,281 shs

Average Volume

2,033,176 shs

Market Capitalization

$1.41 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.2